References
1. Disease GBD, Injury I, Prevalence C. Global, regional, and national
incidence, prevalence, and years lived with disability for 354 diseases
and injuries for 195 countries and territories, 1990-2017: a systematic
analysis for the Global Burden of Disease Study 2017. Lancet.2018;392(10159):1789-858.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The
contributions of hepatitis B virus and hepatitis C virus infections to
cirrhosis and primary liver cancer worldwide. J Hepatol.2006;45(4):529-38.
3. Hepatitis C guidance: AASLD-IDSA recommendations for testing,
managing, and treating adults infected with hepatitis C virus.Hepatology. 2015;62(3):932-54.
4. European Association for Study of L. EASL Recommendations on
Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199-236.
5. Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R,
Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran
and the Potential Impact of Various Treatment Strategies on the Disease
Burden. Hepat Mon. 2016;16(7):e37234-e.
6. Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al.
Liver stiffness is associated with risk of decompensation, liver cancer,
and death in patients with chronic liver diseases: a systematic review
and meta-analysis. Clin Gastroenterol Hepatol.2013;11(12):1573-84.e1-2; quiz e88-9.
7. Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat
S, Tavangar SM, et al. Reversibility of cirrhosis in chronic hepatitis
B. Clin Gastroenterol Hepatol. 2004;2(4):344-7.
8. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert
F, et al. Association between sustained virological response and
all-cause mortality among patients with chronic hepatitis C and advanced
hepatic fibrosis. Jama. 2012;308(24):2584-93.
9. Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E,
Shahzamani K, et al. Pegaferon in hepatitis C: Results of a Multicenter
Study. Middle East J Dig Dis. 2011;3(2):110-4.
10. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E,
Asadi R, et al. Safety and efficacy of locally manufactured pegylated
interferon in hepatitis C patients. Arch Iran Med.2010;13(4):306-12.
11. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al.
Interferon therapy reduces the risk for hepatocellular carcinoma:
national surveillance program of cirrhotic and noncirrhotic patients
with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of
Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med.1999;131(3):174-81.
12. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al.
Effect of interferon therapy on hepatocellular carcinogenesis in
patients with chronic hepatitis type C: A long-term observation study of
1,643 patients using statistical bias correction with proportional
hazard analysis. Hepatology. 1999;29(4):1124-30.
13. Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo
R. Safety of interferon-free therapies for chronic hepatitis C: a
network meta-analysis. J Clin Pharm Ther. 2016;41(5):478-85.
14. Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B,
Nateghi-Baygi A, et al. The Efficacy of 12 Weeks of Sofosbuvir,
Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with
Cirrhosis, Genotypes 1 and 3. Hepat Mon. 2017;17(1):e44564.
15. Merat S. SD1000: High Sustained Viral Response Rate in 1361 Patients
With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose
Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter,
Phase III Clinical Trial. Clin Infect Dis. 2019.
16. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos
NT, et al. Sampling error and intraobserver variation in liver biopsy in
patients with chronic HCV infection. Am J Gastroenterol.2002;97(10):2614-8.
17. Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X.
Transient elastography for diagnosis of advanced fibrosis and portal
hypertension in patients with hepatitis C recurrence after liver
transplantation. Liver Transpl. 2006;12(12):1791-8.
18. Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F,
et al. Liver stiffness measurement as a predictive tool of clinically
significant portal hypertension in patients with compensated hepatitis C
virus or alcohol-related cirrhosis. Aliment Pharmacol Ther.2008;28(9):1102-10.
19. Kim SU, Lee JH, Kim DY, Ahn SH, Jung KS, Choi EH, et al. Prediction
of liver-related events using fibroscan in chronic hepatitis B patients
showing advanced liver fibrosis. PLoS One. 2012;7(5):e36676.
20. Corpechot C, Carrat F, Poujol-Robert A, Gaouar F, Wendum D,
Chazouillères O, et al. Noninvasive elastography-based assessment of
liver fibrosis progression and prognosis in primary biliary cirrhosis.Hepatology. 2012;56(1):198-208.
21. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, et
al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in
patients with chronic hepatitis C virus infection. Cancer.2003;97(12):3036-43.
22. Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, Rakhshani N,
Tavangar SM, Sohrabpour AA, et al. Reversibility of cirrhosis in
autoimmune hepatitis. Am J Med. 2004;117(2):125-9.
23. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali S,
Rakhshani N, Tavangar SM, et al. Impact of immunosuppressive treatment
on liver fibrosis in autoimmune hepatitis. Dig Dis Sci.2005;50(3):547-51.
24. Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, et al.
Long-term treatment with entecavir induces reversal of advanced fibrosis
or cirrhosis in patients with chronic hepatitis B. Clin
Gastroenterol Hepatol. 2011;9(3):274-6.
25. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et
al. Regression of cirrhosis during treatment with tenofovir disoproxil
fumarate for chronic hepatitis B: a 5-year open-label follow-up study.Lancet. 2013;381(9865):468-75.
26. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP,
Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients
successfully treated for chronic hepatitis C. Gastroenterology.2008;135(3):821-9.
27. Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ,
et al. Effect of peginterferon alfa-2a on liver histology in chronic
hepatitis C: a meta-analysis of individual patient data.Hepatology. 2004;39(2):333-42.
28. Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Kataoka S, et al.
Improvement of liver stiffness in patients with hepatitis C virus
infection who received direct-acting antiviral therapy and achieved
sustained virological response. J Gastroenterol Hepatol.2017;32(12):1982-8.
29. Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura
Y, et al. Serial changes in liver stiffness and controlled attenuation
parameter following direct-acting antiviral therapy against hepatitis C
virus genotype 1b. J Med Virol. 2018;90(2):313-9.
30. Elsharkawy A, Alem SA, Fouad R, El Raziky M, El Akel W, Abdo M, et
al. Changes in liver stiffness measurements and fibrosis scores
following sofosbuvir based treatment regimens without interferon.J Gastroenterol Hepatol. 2017;32(9):1624-30.
31. Soliman H, Ziada D, Salama M, Hamisa M, Badawi R, Hawash N, et al.
Predictors for Fibrosis Regression in Chronic HCV Patients after the
Treatment with DAAS: Results of a Real-world Cohort Study. Endocr
Metab Immune Disord Drug Targets. 2020;20(1):104-11.
32. Lledó GM, Carrasco I, Benítez-Gutiérrez LM, Arias A, Royuela A,
Requena S, et al. Regression of liver fibrosis after curing chronic
hepatitis C with oral antivirals in patients with and without HIV
coinfection. Aids. 2018;32(16):2347-52.
33. Tag-Adeen M, Sabra AM, Akazawa Y, Ohnita K, Nakao K. Impact of
hepatitis C virus genotype-4 eradication following direct acting
antivirals on liver stiffness measurement. Hepat Med.2017;9:45-53.
34. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et
al. Impact of pegylated interferon alfa-2b and ribavirin on liver
fibrosis in patients with chronic hepatitis C. Gastroenterology.2002;122(5):1303-13.
35. Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, et al.
Liver stiffness decrease after effective antiviral therapy in patients
with chronic hepatitis C: Longitudinal study using FibroScan. J
Gastroenterol Hepatol. 2010;25(5):964-9.
36. Knop V, Mauss S, Goeser T, Geier A, Zimmermann T, Herzer K, et al.
Dynamics of liver stiffness by transient elastography in patients with
chronic hepatitis C virus infection receiving direct-acting antiviral
therapy-Results from the German Hepatitis C-Registry. J Viral
Hepat. 2020.
37. Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, et
al. High serum angiopoietin-2 level predicts non-regression of liver
stiffness measurement-based liver fibrosis stage after direct-acting
antiviral therapy for hepatitis C. Hepatol Res. 2020.
38. Persico M, Rosato V, Aglitti A, Precone D, Corrado M, De Luna A, et
al. Sustained virological response by direct antiviral agents in HCV
leads to an early and significant improvement of liver fibrosis.Antivir Ther. 2018;23(2):129-38.
39. Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, et
al. Liver steatosis and dyslipidemia after HCV eradication by direct
acting antiviral agents are synergistic risks of atherosclerosis.PLoS One. 2018;13(12):e0209615.
40. Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, et al.
Viral eradication reduces both liver stiffness and steatosis in patients
with chronic hepatitis C virus infection who received direct-acting
anti-viral therapy. Aliment Pharmacol Ther. 2018;47(7):1012-22.
41. Shimizu K, Soroida Y, Sato M, Hikita H, Kobayashi T, Endo M, et al.
Eradication of hepatitis C virus is associated with the attenuation of
steatosis as evaluated using a controlled attenuation parameter.Sci Rep. 2018;8(1):7845.
42. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et
al. The lipid droplet is an important organelle for hepatitis C virus
production. Nat Cell Biol. 2007;9(9):1089-97.
43. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y,
et al. Hepatitis C virus core protein inhibits microsomal triglyceride
transfer protein activity and very low density lipoprotein secretion: a
model of viral-related steatosis. Faseb j. 2002;16(2):185-94.
44. Syed GH, Tang H, Khan M, Hassanein T, Liu J, Siddiqui A. Hepatitis C
virus stimulates low-density lipoprotein receptor expression to
facilitate viral propagation. J Virol. 2014;88(5):2519-29.
45. Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M,
et al. Hepatic steatosis in chronic hepatitis C is a significant risk
factor for developing hepatocellular carcinoma independent of age, sex,
obesity, fibrosis stage and response to interferon therapy.Hepatol Res. 2010;40(9):870-7.
46. Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, et
al. Hepatic steatosis as a possible risk factor for the development of
hepatocellular carcinoma after eradication of hepatitis C virus with
antiviral therapy in patients with chronic hepatitis C. World J
Gastroenterol. 2007;13(39):5180-7.